{"id":389104,"date":"2023-12-19T00:00:00","date_gmt":"2023-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2023-biopharma-psoriatic-arthritis-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:29","modified_gmt":"2026-03-31T10:31:29","slug":"dlsfim0006-2023-biopharma-psoriatic-arthritis-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2023-biopharma-psoriatic-arthritis-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Psoriatic Arthritis | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents\u2014AbbVie\u2019s Rinvoq and Skyrizi and UCB\u2019s bimekizumab. Furthermore, a series of approvals expected in the next decade will likely present a challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies, and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to garner substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS\u2019s deucravacitinib) and an IL-23 inhibitor (Sun Pharma\u2019s tildrakizumab) will also create interesting market dynamics.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in the various markets under study react to these less-expensive therapies?<\/li>\n<li>How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What are physician perceptions of these therapies?<\/li>\n<li>Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? Which novel mechanisms of action are considered good clinical targets for this disease?<\/li>\n<li>Which unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?<\/li>\n<\/ul>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 31 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2032, segmented by brands \/ generics.<\/p>\n<p>Emerging therapies: Phase 3\/PR: 2 drugs; Phase 2: 7 drugs.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389104","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389104\/revisions"}],"predecessor-version":[{"id":576013,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389104\/revisions\/576013"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}